Document Detail

Chromogranin A: is it a useful marker of neuroendocrine tumors?
MedLine Citation:
PMID:  17513802     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) cell hyperplasia, and in healthy participants (HPs). PATIENTS AND METHODS: Two hundred thirty-eight patients with NETs, 42 patients with CAG with or without ECL cell hyperplasia, and 48 HPs were studied. All patients underwent a baseline visit, biochemical routine check-up, imaging techniques, endoscopy, and histologic determination. RESULTS: CgA plasma levels were higher in patients with NETs compared with CAG patients or HPs (P < .001). In the NET group, we observed higher CgA levels in patients with diffuse disease compared with patients with local or hepatic disease (P < .001). CgA plasma levels were significantly higher in patients with Zollinger-Ellison syndrome compared with other types of endocrine tumors (P < .001). We found the best cutoff range between HPs and NET patients to be 18 to 19 U/L (sensitivity, 85.3%; specificity, 95.8%). Comparing all participants without neoplasia (HPs, CAG patients, and disease-free patients) and patients with endocrine tumors, the best cutoff range was 31 to 32 U/L (sensitivity, 75.3%; specificity, 84.2%). Setting the specificity at 95%, the cutoff range was 84 to 87 U/L (sensitivity, 55%). CONCLUSION: Our study confirms the high specificity and sensitivity of CgA in diagnosing an endocrine tumor. It is necessary to use a cutoff range of 84 to 87 U/L to obtain a high specificity in diagnosing NETs, with the aim of excluding patients in whom the CgA was elevated as a result of other non-neoplastic diseases.
Davide Campana; Francesca Nori; Lidya Piscitelli; Antonio Maria Morselli-Labate; Raffaele Pezzilli; Roberto Corinaldesi; Paola Tomassetti
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  25     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-21     Completed Date:  2007-06-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1967-73     Citation Subset:  IM    
Department of Internal Medicine and Gastroenterology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Case-Control Studies
Chromogranin A / blood*
Diagnosis, Differential
Enterochromaffin-like Cells / pathology*
Gastritis, Atrophic / blood,  diagnosis*
Middle Aged
Neuroendocrine Tumors / blood,  diagnosis*
Sensitivity and Specificity
Tumor Markers, Biological / blood*
Zollinger-Ellison Syndrome / blood,  diagnosis*
Reg. No./Substance:
0/CHGA protein, human; 0/Chromogranin A; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell tr...
Next Document:  Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive s...